DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Dextrose provides a source of calories and fluid, correcting hypoglycemia. Sodium chloride and potassium chloride replenish electrolytes and maintain osmotic balance.
| Metabolism | Dextrose undergoes glycolysis and oxidative metabolism via the Krebs cycle; potassium is primarily excreted renally; sodium and chloride are handled by renal regulation. |
| Excretion | Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion. Sodium and chloride are primarily excreted renally, with >90% eliminated unchanged; potassium is >90% renally excreted, with minor fecal (approximately 5%) and negligible biliary elimination. |
| Half-life | The components do not have a classical half-life. Dextrose has a distribution half-life of a few minutes and an elimination half-life of approximately 1-2 hours due to cellular uptake and metabolism. Sodium and chloride have a volume-dependent half-life; potassium's elimination half-life is approximately 12-24 hours, prolonged in renal impairment. |
| Protein binding | Dextrose, sodium, chloride, and potassium are not significantly protein-bound (<1%); potassium has minimal binding (~3% to albumin). |
| Volume of Distribution | Dextrose 0.2-0.3 L/kg (mainly extracellular); sodium and chloride distribution approximates extracellular fluid volume (~0.2 L/kg); potassium distribution is 0.4-0.5 L/kg (mainly intracellular). |
| Bioavailability | Intravenous: 100% for all components. Not administered orally for dextrose 5% with electrolytes due to GI tolerability issues; oral potassium has bioavailability ~90%. |
| Onset of Action | Intravenous: immediate for volume expansion; dextrose metabolism begins within minutes; potassium distribution occurs over minutes to hours. |
| Duration of Action | Volume effects last 1-2 hours; dextrose's caloric effect persists for 1-2 hours; potassium's effect on serum concentration lasts 4-6 hours, but tissue repletion requires longer infusion (e.g., 10-20 hours for deficit correction). |
| Molecular Weight | 180.16 |
Intravenous infusion: 1000 mL administered at a rate of 125 mL/hour over 8 hours; typical dosing range 1-3 L per 24 hours titrated based on electrolyte levels, fluid status, and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30-50 mL/min: reduce potassium content or use alternative; eGFR 15-29 mL/min: avoid if possible, use with caution and monitor potassium closely; eGFR <15 mL/min: contraindicated unless replacement therapy. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: monitor potassium and glucose levels; Child-Pugh Class C: use with caution, monitor for fluid overload and electrolyte imbalance. |
| Pediatric use | Dose based on weight and electrolyte needs; typical infusion rate 2-6 mL/kg/hour for maintenance; adjust potassium to 0.5-1 mEq/kg/day for replacement; maximum infusion rate not to exceed 1 mEq/kg/hour for potassium. |
| Geriatric use | Use lower end of dosing range due to decreased renal function; monitor for fluid overload, hyperkalemia, and glucose intolerance; typical rate 50-100 mL/hour adjusted based on renal function and volume status. |
| 1st trimester | Dextrose and electrolytes are generally considered safe in recommended doses during the first trimester as they are essential for maternal and fetal nutrition. Potassium chloride at high doses may cause hyperkalemia; use with caution. |
| 2nd trimester | Safe in recommended doses for fluid and electrolyte maintenance; monitor potassium levels to avoid hyperkalemia. |
| 3rd trimester | Safe in recommended doses; caution in conditions predisposing to hyperkalemia (e.g., preeclampsia, renal impairment). |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Dextrose and electrolytes freely cross the placenta via passive diffusion and active transport. Potassium chloride transfer is regulated by placental transporters. |
| Breastfeeding | Dextrose and electrolytes are normal constituents of breast milk. Potassium chloride at this concentration is unlikely to affect the infant if maternal serum levels are normal. Use with caution in cases of maternal hyperkalemia. |
| Lactation Rating | Safe |
| Teratogenic Risk | Dextrose, sodium chloride, and potassium chloride are essential nutrients and electrolytes; no teratogenic effects are expected at therapeutic doses. Trimester 1: No known fetal risk. Trimester 2 & 3: Use as clinically indicated; excess potassium or sodium may cause maternal electrolyte disturbances affecting fetal fluid balance, but no direct teratogenicity. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, glucose) and renal function; fetal heart rate monitoring if maternal electrolyte abnormalities occur; fluid balance assessment to avoid overload. |
| Fertility Effects | No known effects on fertility at therapeutic doses. |
■ FDA Black Box Warning
None for this specific combination; however, potassium chloride carries risk of hyperkalemia and cardiac arrest if administered too rapidly or in renal impairment.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydration with hyperkalemiaConcurrent use of potassium-sparing diuretics or ACE inhibitors with high potassium levels
| Precautions | Monitor serum electrolytes, renal function, and fluid balance, Risk of hyperkalemia, especially in renal impairment, Risk of fluid overload, pulmonary edema, Use with caution in patients with heart failure, renal impairment, or hyperkalemia, Do not use as a potassium replacement in severe hyperkalemia |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, potatoes, spinach) unless directed by healthcare provider. Limit sodium intake as per dietary recommendations. No significant food interactions with dextrose. |
| Clinical Pearls | Do not administer if solution is discolored or contains precipitate. Monitor serum potassium closely, especially in renal impairment. Infusion rate should not exceed 0.5 mEq/kg/hr for potassium. Use with caution in patients with heart failure or fluid overload due to sodium content. |
| Patient Advice | Report any pain, redness, or swelling at the IV site immediately. · This solution contains potassium; do not consume additional potassium supplements without consulting your doctor. · Inform your doctor if you have kidney problems or are on a low-sodium diet. · You may experience a cold sensation at the infusion site; notify staff if discomfort persists. |
Loading safety data…